Finerenone for adults with IgA nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective interventional trial testing finerenone in adults with biopsy-confirmed IgA nephropathy and significant albuminuria. Eligible participants must have 24-hour urine albumin excretion over 300 mg, controlled blood pressure, and stable treatment with RAAS blockers and/or SGLT2 inhibitors for at least three months. Participants will receive finerenone and be monitored for changes in albuminuria, kidney function (eGFR), serum potassium, and adverse events. The trial is conducted at a single center (Botkin Hospital, Moscow) with predefined exclusion criteria including low eGFR, prior transplant, active malignancy, ongoing immunosuppression, and recent major cardiovascular events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (\> 18 years) with the primary IgAN diagnosed by kidney biopsy;
* Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;
* Blood pressure \< 140/90 mm Hg
* 24-hour urinary albumin excretion \> 300 mg

Exclusion Criteria:

* Kidney transplantation in medical history
* Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;
* Heart failure with ejection fraction \<40%;
* Acute myocardial infarction and/or stroke less then 3 months before including in trial;
* Presence ANCA in serum
* Ongoing immunosuppressive treatment
* eGFR \< 20 ml/min
* Pregnancy and breastfeeding
* Uncontrolled blood pressure

Where it's running

• Botkin Hospital
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Evgeny Shytov, PhD
• Email: shutov_e_v@mail.ru
• Phone: +7 499 490 03 03

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JADE101 in IgA Nephropathy (phase 3, blinded)

  This phase 3 study tests whether JADE101 helps adults with IgA nephropathy more than a placebo.

  Recruiting at 4 sites Phase 3 Jade Biosciences, Inc. · Arvada, Colorado and 3 other locations · NCT07902817

• Personalized IgA Nephropathy treatment guided by Gd-IgA1 monitoring

  This study tests whether regularly checking a biomarker called Gd-IgA1 to guide treatment with Nefecon or telitacicept helps people with IgA nephropathy or related nephritis respond better.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07822100

• Long-term safety and effectiveness of HSK39297 tablets in IgA nephropathy patients who completed prior study

  This phase 2 trial tests whether taking HSK39297 once daily for IgA nephropathy is safe over the long term and helps reduce protein in the urine for patients who completed a previous study and meet criteria.

  Recruiting Phase 2 Haisco Pharmaceutical Group Co., Ltd. · Beijing and 1 other locations · NCT07616700

• Everest001: a medicine for certain kidney diseases to see if it helps adults

  This study tests EVER001 in adults with FSGS, MCD, or IgA nephropathy to see if it can help reduce protein in the urine and improve kidney function.

  Recruiting at 2 sites Phase 2 Everest Medicines (China) Co.,Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07614477

• Nefecon as a maintenance therapy to prevent relapse in IgA nephropathy

  This study tests whether continuing Nefecon after initial remission can lower the chance of relapse in adults with IgA nephropathy.

  Recruiting Phase 4 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07604311

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.